AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10375362 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (0.9 mg/dl iron) followed by term formula (0.5 mg/dl iron)
Number of subjects: 78
Study 7770590 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 0
Study 7770590 — intervention group
Group type: COMPARATOR
Intervention: Structured interview
Number of subjects: 0
Study 7770590 — intervention group
Group type: COMPARATOR
Intervention: Choice of procedure
Number of subjects: 0
Study 2216187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefazolin administered intramuscularly
Number of subjects: 772
Study 2216187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefazolin administered intravenously
Number of subjects: 772
Study 319541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 120 mg/d
Number of subjects: 93
Study 319541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 120 mg/d and 210 mg/d pooled results
Number of subjects: 93
Study 319541 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 240 mg/d
Number of subjects: 93
Study 319541 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 360 mg/d
Number of subjects: 93
Study 31270036 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroCTO (CASTLE) score
Number of subjects: 660
Study 31270036 — intervention group
Group type: COMPARATOR
Intervention: J‐CTO score
Number of subjects: 660
Study 31270036 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroCTO (CASTLE) score for complex procedures (J‐CTO ≥3 or EuroCTO [CASTLE] ≥4)
Number of subjects: 660
Study 31270036 — intervention group
Group type: COMPARATOR
Intervention: J‐CTO score for complex procedures (J‐CTO ≥3 or EuroCTO [CASTLE] ≥4)
Number of subjects: 660
Study 31367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail subjects
Number of subjects: 26
Study 31367728 — intervention group
Group type: COMPARATOR
Intervention: Pre-frail subjects
Number of subjects: 26
Study 31367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Total SPPB
Number of subjects: 26
Study 31367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance SPPB sub-score
Number of subjects: 26
Study 31367728 — intervention group
Group type: EXPERIMENTAL
Intervention: MNA score
Number of subjects: 26
Study 31367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip flexor strength
Number of subjects: 26
Study 31367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking time
Number of subjects: 26
Study 31367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising chair sub-score
Number of subjects: 26
Study 29046265 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Web‐centered training
Number of subjects: 156
Study 29046265 — intervention group
Group type: COMPARATOR
Intervention: Independent Web‐centered training
Number of subjects: 156
Study 29046265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 156
Study 24660151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dextrose 10% given at 3 and 6 hours prior to the operation
Number of subjects: 120
Study 24660151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dextrose intervention)
Number of subjects: 120
Study 24343071 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with 40 mg parecoxib sodium and infiltration of 0.5% ropivacaine (20 mL)
Number of subjects: 60
Study 24343071 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 mL) intravenously before anesthesia induction and infiltration of 0.5% ropivacaine (20 mL)
Number of subjects: 60
Study 20610322 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 340
Study 20610322 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 340
Study 18840791 — intervention group
Group type: EXPERIMENTAL
Intervention: Neptune Pad (n = 100)
Number of subjects: 201
Study 18840791 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual compression (n = 101)
Number of subjects: 201
Study 17086053 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard vaginal gel
Number of subjects: 55
Study 12811500 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (20 mg twice daily)
Number of subjects: 358
Study 12811500 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin (5 mg twice daily)
Number of subjects: 358
Study 10743692 — intervention group
Group type: COMPARATOR
Intervention: Systemic venous drainage (SV)
Number of subjects: 30
Study 10743692 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal venous drainage (PV)
Number of subjects: 30
Study 10743692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SV and PV)
Number of subjects: 30
Study 1463527 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg b.i.d.)
Number of subjects: 336
Study 1463527 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg t.i.d.)
Number of subjects: 336
Study 6509782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor blockade (domperidone 10 mg i.v.) in acromegalic subjects
Number of subjects: 15
Study 6509782 — intervention group
Group type: COMPARATOR
Intervention: Dopamine receptor blockade (domperidone 10 mg i.v.) in normal controls
Number of subjects: 15
Study 6509782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular growth hormone (three injections of 4 IU) before domperidone
Number of subjects: 15
Study 6509782 — intervention group
Group type: COMPARATOR
Intervention: Saline (equivalent volume) before domperidone
Number of subjects: 15
Study 30769128 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (20 Hz, double cone coil over vertex)
Number of subjects: 31
Study 30769128 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 31
Study 30769128 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 31
Study 30083962 — intervention group
Group type: EXPERIMENTAL
Intervention: tivantinib 360 mg PO BID
Number of subjects: 80
Study 30083962 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 27234001 — intervention group
Group type: EXPERIMENTAL
Intervention: Can Do Treatment (CDT)
Number of subjects: 140
Study 25142708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 7112
Study 25142708 — intervention group
Group type: COMPARATOR
Intervention: No nitrous oxide
Number of subjects: 7112
Study 23113512 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser vaporesection of the prostate
Number of subjects: 98
Study 23113512 — intervention group
Group type: COMPARATOR
Intervention: Transurethral electrovaporization of the prostate
Number of subjects: 98
Study 23113512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 98
Study 20420991 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus rocking-chair intervention
Number of subjects: 66
Study 20420991 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study 18036467 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one coaching by an opinion leader
Number of subjects: 6
Study 18036467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study 16240061 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction (RY)
Number of subjects: 50
Study 16240061 — intervention group
Group type: COMPARATOR
Intervention: Billroth I reconstruction (B-I)
Number of subjects: 50
Study 12038883 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based family-support intervention
Number of subjects: 136
Study 12038883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 8951481 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 57
Study 8951481 — intervention group
Group type: COMPARATOR
Intervention: External radiation therapy
Number of subjects: 57
Study 1916523 — intervention group
Group type: EXPERIMENTAL
Intervention: Real vibro-acoustic stimulation
Number of subjects: 25
Study 1916523 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study 7128259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (routine well-child care plus discussions regarding infant social development)
Number of subjects: 32
Study 7128259 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (routine well-child care plus discussions regarding accident prevention and nutrition)
Number of subjects: 32
Study 31773110 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric rehabilitation protocol augmented with the Accelerated Recovery Performance trainer protocol
Number of subjects: 25
Study 31773110 — intervention group
Group type: COMPARATOR
Intervention: Isometric rehabilitation protocol alone
Number of subjects: 25
Study 28199397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide/timolol
Number of subjects: 62
Study 28199397 — intervention group
Group type: COMPARATOR
Intervention: Oral acetazolamide and topical dexamethasone
Number of subjects: 62
Study 26757325 — intervention group
Group type: EXPERIMENTAL
Intervention: Denzir (DZ)
Number of subjects: 18
Study 26757325 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Ceram Zirconia (InZ)
Number of subjects: 18
Study 26757325 — intervention group
Group type: COMPARATOR
Intervention: Both groups (DZ and InZ)
Number of subjects: 18
Study 24456143 — intervention group
Group type: COMPARATOR
Intervention: Post-fatigue laser treatment
Number of subjects: 27
Study 24456143 — intervention group
Group type: COMPARATOR
Intervention: Pre-fatigue laser treatment
Number of subjects: 27
Study 24456143 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 22925276 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 71
Study 22925276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 21134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily for 12 weeks
Number of subjects: 431
Study 21134997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 21134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 431
Study 17166314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Number of subjects: 0
Study 17166314 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study 14738324 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 0
Study 14738324 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (OC)
Number of subjects: 0
Study 14738324 — intervention group
Group type: COMPARATOR
Intervention: Preoperative period
Number of subjects: 0
Study 11872510 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural, interpersonal, cognitive, problem-solving and other psychotherapies
Number of subjects: 0
Study 11872510 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 9500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy manipulation (told alcohol would impair task performance)
Number of subjects: 120
Study 9500307 — intervention group
Group type: COMPARATOR
Intervention: Expectancy manipulation (told alcohol had no effect on performance)
Number of subjects: 120
Study 9500307 — intervention group
Group type: COMPARATOR
Intervention: Expectancy manipulation (effects of alcohol were unknown)
Number of subjects: 120
Study 7651472 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 85
Study 7651472 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 85
Study 1669525 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2182
Study 1669525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 2182
Study 1669525 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 2182
Study 1669525 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 2182
Study 1669525 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 2182
Study 1669525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 2182
Study 1669525 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 2182
Study 6893692 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine (M) 4 mg, single dose
Number of subjects: 38
Study 6893692 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (M), prolonged treatment
Number of subjects: 38
Study 6893692 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine (M), single dose
Number of subjects: 38
Study 30921748 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive therapies
Number of subjects: 61
Study 30921748 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma scores
Number of subjects: 61
Study 27886976 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled allergen
Number of subjects: 18
Study 27886976 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) and allergen co-exposure
Number of subjects: 18
Study 27886976 — intervention group
Group type: COMPARATOR
Intervention: Filtered air followed by instilled allergen
Number of subjects: 18
Study 27886976 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 27886976 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum leptin and resistin
Number of subjects: 18
Study 25262100 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 576
Study 25262100 — intervention group
Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 576
Study 25262100 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 576
Study 23322203 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures for women aged 50-59
Number of subjects: 0
Study 23322203 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures for women aged 40-49
Number of subjects: 0
Study 23322203 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition rates for women aged 40-49
Number of subjects: 0
Study 23322203 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition rates for women aged 50-59
Number of subjects: 0
Study 23322203 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a risk factor
Number of subjects: 0
Study 23322203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for women aged 40-49
Number of subjects: 0
Study 23322203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for women aged 50-59
Number of subjects: 0
Study 21335940 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 126
Study 21335940 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheterization
Number of subjects: 126
Study 21335940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study 19587249 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart reminder plus mailed patient education (CR+PtEd)
Number of subjects: 204
Study 19587249 — intervention group
Group type: COMPARATOR
Intervention: Chart reminder alone (CR)
Number of subjects: 204
Study 19587249 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study 17349495 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage and acupuncture
Number of subjects: 138
Study 17349495 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 14981009 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol/kg per minute) for 72 hours
Number of subjects: 21
Study 14981009 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 21
Study 11316375 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg + Relapse Prevention Therapy (RP)
Number of subjects: 85
Study 11316375 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 0 mg + Relapse Prevention Therapy (RP)
Number of subjects: 85
Study 11316375 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 50 mg + Drug Counseling
Number of subjects: 85
Study 11316375 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 0 mg + Drug Counseling
Number of subjects: 85
Study 9868707 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg MDE
Number of subjects: 16
Study 9868707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7980370 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Control over the specimen
Number of subjects: 16
Study 7980370 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to attend closely to the features of the specimen
Number of subjects: 16
Study 7980370 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to attend closely to the specimen
Number of subjects: 16
Study 7980370 — intervention group
Group type: COMPARATOR
Intervention: Partner-Control over the specimen
Number of subjects: 16
Study 7980370 — intervention group
Group type: COMPARATOR
Intervention: Instructions to attend closely to one's bodily fear reactions
Number of subjects: 16
Study 7980370 — intervention group
Group type: COMPARATOR
Intervention: Instructions to attend to one's bodily reactions
Number of subjects: 16
Study 2658525 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 10 mg/day
Number of subjects: 302
Study 2658525 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 20 mg/day
Number of subjects: 302
Study 2658525 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg/day
Number of subjects: 302
Study 2658525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 901695 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg metoprolol tartrate
Number of subjects: 6
Study 901695 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol tartrate
Number of subjects: 6
Study 901695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 901695 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 6
Study 31025258 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium 0.6 mg·kg−1·hr−1
Number of subjects: 0
Study 31025258 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (control)
Number of subjects: 0
Study 31025258 — intervention group
Group type: COMPARATOR
Intervention: Control (NaCl 0.9%)
Number of subjects: 0
Study 29178954 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal silver (CS) nasal spray, administered twice daily for six weeks
Number of subjects: 20
Study 29178954 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal spray, administered twice daily for six weeks
Number of subjects: 20
Study 25467016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg orally daily)
Number of subjects: 128
Study 25467016 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly)
Number of subjects: 128
Study 25467016 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Lapatinib (at the same doses)
Number of subjects: 128
Study 25467016 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 23796741 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 1980
Study 23796741 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1980
Study 21153021 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg infused once yearly
Number of subjects: 2127
Study 21153021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 21153021 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 2127
Study 18294736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) added to approved AD therapies for 6 months, then discontinued, and resumed for another 9 months
Number of subjects: 8
Study 18028126 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical recombinant human acidic fibroblast growth factor (rh‐aFGF)
Number of subjects: 0
Study 18028126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15040968 — intervention group
Group type: EXPERIMENTAL
Intervention: Insidious onset neck pain
Number of subjects: 75
Study 15040968 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash injury neck pain
Number of subjects: 75
Study 15040968 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic control subjects
Number of subjects: 75
Study 11772241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid (ALA) in photodynamic therapy (PDT)
Number of subjects: 0
Study 11772241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid (ALA) as a photosensitiser
Number of subjects: 0
Study 11772241 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-induced porphyrins fluorescence
Number of subjects: 0
Study 11772241 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA treatment for non-tumoural applications
Number of subjects: 0
Study 9133891 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude peanut oil
Number of subjects: 60
Study 9133891 — intervention group
Group type: COMPARATOR
Intervention: Refined peanut oil
Number of subjects: 60
Study 7909853 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (42 micrograms inhaled twice daily)
Number of subjects: 322
Study 7909853 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (180 micrograms inhaled four times daily)
Number of subjects: 322
Study 7909853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four times a day)
Number of subjects: 322
Study 3630820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T-PP
Number of subjects: 412
Study 3630820 — intervention group
Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 412
Study 30098961 — intervention group
Group type: EXPERIMENTAL
Intervention: 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g
Number of subjects: 108
Study 30098961 — intervention group
Group type: EXPERIMENTAL
Intervention: Almost pure EPA at 2 g
Number of subjects: 108